FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

225 ILCS 85/16a and 68 Ill. Adm. Code 1330.550 require nonresident pharmacies that dispense for Illinois residents and mail, ship or deliver prescription drugs into Illinois to hold an Illinois nonresident pharmacy license/registration from the Illinois Department of Financial and Professional Regulation (IDFPR). Conditions include a home-state license, disclosure of officers and dispensing pharmacists, cooperation with the Board, readily retrievable records of drugs dispensed to Illinois residents, and a toll-free pharmacist line (at least 6 days/40 hours per week) printed on every label. Rule 1330.550 states that beginning January 1, 2026 the pharmacist-in-charge of a nonresident pharmacy must be licensed in Illinois; other pharmacists need not be. The IDFPR application (packet updated 1/15/26) asks nonresident applicants for a home-state certification of licensure, home-state pharmacy and controlled-substance licenses, DEA registration and the most recent inspection report, and lists 'Sterile Compounding Pharmacy' as an operation type to check; nonresident pharmacies must follow Illinois law when filling for Illinois residents unless it directly conflicts with home-state law.

The official ILGA statute site blocked automated fetching; the statute text was confirmed from FindLaw's copy (current as of 2025-01-01) and the rule from Cornell LII. The Illinois-licensed PIC requirement for nonresident pharmacies took effect 2026-01-01 (68 Ill. Adm. Code 1330.550, 48 Ill. Reg. 10225). No separate nonresident sterile-compounding license beyond checking the sterile compounding operation type was found.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

68 Ill. Adm. Code 1330.640(b) defines office use as a practitioner administering a non-patient-specific compounded drug in the office or a health care facility/treatment setting. Under 1330.640(d) a pharmacist may dispense and deliver a reasonable quantity of a nonsterile compounded drug to a practitioner for office use if the quantity does not exceed what the practitioner expects to use before the beyond-use date, is reasonable for the practice, and does not exceed the pharmacy's capacity to compound to USP-consistent standards; the pharmacy must keep records for 5 years (practitioner, drug, compounding and delivery dates, lot number, BUD) and label the product with lot, BUD, storage and 'For Office Use Only - Not for Resale.' Under 1330.640(c) sterile compounding for office use is prohibited unless the pharmacy fully complies with 21 USC 353b, including registering as an outsourcing facility and being licensed as a wholesale drug distributor under 225 ILCS 120; sterile compounded drugs may still be delivered to the prescriber's office on a patient-specific prescription. IDFPR enforces. The nonsterile office-use allowance is broader than FDA's view that 503A compounding requires patient-specific prescriptions.

The rule does not say whether a nonresident pharmacy may ship nonsterile office-use stock into Illinois; nonresident pharmacies must follow Illinois law when serving Illinois (1330.550), so the same limits would apply, but this is not expressly addressed. The official ILGA/JCAR host blocked automated fetching; text confirmed via Cornell LII. Stale-source flag: the controlling text is dated 2024-06-28 (more than 2 years before 2026-09-23); it is the latest version found, but confirm with the board that it is still current.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

The Wholesale Drug Distribution Licensing Act requires every nonresident wholesale distributor that ships prescription drugs into Illinois to be licensed in Illinois (225 ILCS 120/25), and the Act's definitions include manufacturers within 'wholesale drug distributor' (225 ILCS 120/15). The pharmacy compounding rule ties office-use sterile compounding to both federal 503B registration and an Illinois wholesale drug distributor license (68 Ill. Adm. Code 1330.640(c)). The IDFPR wholesale application (packet updated 7/24/25) asks out-of-state facilities for a home-state certification of licensure, home-state distributor and controlled-substance licenses, DEA registration and the most recent inspection report, and offers a 'Manufacturer' distributor category; IDFPR's license list has no outsourcing-facility category. Dispensing patient-specific prescriptions to Illinois residents falls under the nonresident pharmacy license (225 ILCS 85/16a).

No Illinois statute or rule found that names an 'outsourcing facility' license; the wholesale-distributor route is inferred from 225 ILCS 120/25 plus the express reference in 1330.640(c). It is worth confirming the credential type with IDFPR's Drug Compliance Unit for a specific 503B. The official ILGA host blocked automated fetching; statute text confirmed from FindLaw's copy.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Illinois is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

720 ILCS 570/302(a) requires every person who dispenses controlled substances in Illinois to obtain a registration from the Department of Financial and Professional Regulation, and 'dispense' is defined to include prescribing and administering (570/102). IDFPR's application instructions state that every person who prescribes and/or stores or dispenses controlled substances in Illinois must obtain the license, that a separate registration is required for each place of practice where controlled substances are stored or dispensed, that the fee is $5, and that the state registration is a prerequisite for federal DEA registration with the same address. Separate CS license types exist for physicians, PAs, APRNs and full-practice APRNs; the physician CS license renews with the physician license (the 2026 renewal deadline was extended to Aug. 31, 2026).

Since July 2024 IDFPR lets physicians, PAs and APRNs apply for the CS license at the same time as the professional license. A CS registration is not issued on a temporary license. Per-location: separate registration where controlled substances are stored or dispensed.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Every prescriber with an Illinois controlled substance license must register with the PMP. Under current 720 ILCS 570/314.5(c-5), the prescriber or designee must document an attempt to access the PMP when providing an initial prescription for Schedule II narcotics such as opioids, except for oncology or palliative care or a 7-day or less supply from a hospital emergency department for an acute, traumatic condition. The section does not apply to hospital or institutional inpatients/residents. P.A. 104-512 (effective 1-1-2027) changes the trigger to initial prescriptions for Schedule II stimulants and all prescriptions for Schedule II opioids and Schedule IV benzodiazepines.

Testosterone (C-III) is not caught under either version. Change pending: P.A. 104-512 effective January 1, 2027 widens the mandate (Schedule II stimulants initial Rx; every Schedule II opioid and Schedule IV benzodiazepine Rx) and adds a safe harbor for registration failures caused by technical problems.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

225 ILCS 60/33 authorizes physicians licensed in all branches to purchase and dispense legend drugs; dispensing must be the physician's personal act or be directly supervised. Except for samples or up to a 72-hour supply, the physician keeps a prescription file as the Pharmacy Practice Act requires. Labels must show date, patient, dispenser's last name, directions, and drug name, dose and quantity. Before dispensing, the physician must offer a written prescription the patient may fill anywhere. Controlled substances also require an Illinois controlled substance license.

Section last amended by P.A. 98-1140 (eff. 12-30-14) and is scheduled for repeal January 1, 2032 with the Medical Practice Act sunset. Source older than 2 years but still the current text at access.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

225 ILCS 60/49.5 makes practicing telemedicine on Illinois patients without an Illinois license or permit subject to penalties; excluded are periodic consultations with an Illinois licensee, second opinions, follow-up care after treatment in the provider's own state, and care for existing patients who are traveling. Telehealth prescribing follows the ordinary standard of care; no Illinois statute found adds an in-person requirement or a telehealth-specific controlled-substance limit. An Illinois controlled substance license is needed to prescribe testosterone. IMLC: member.

Section 49.5 is scheduled for repeal January 1, 2032 with the Medical Practice Act sunset.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

Section 54.2 of the Medical Practice Act says nothing limits a physician's delegation of patient-care tasks to an RN, LPN or other licensee acting within their own licensing act, and that delegation may be made by any means, including standing orders, protocols, guidelines or verbal orders. In an office setting and within a physician-patient relationship, a physician may delegate to a trained unlicensed person only if a licensed health care professional is on site. Delegated tasks must be within the physician's own scope and training. No Illinois rule specific to neuromodulators or fillers was found.

Answer rests on the general delegation statute. IDFPR/Board of Nursing guidance on cosmetic injectables was not located.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

225 ILCS 60/54.2 allows delegation of patient-care tasks to RNs and LPNs within their licensing act, by any method including standing orders and protocols, and requires delegated tasks to be within the context of a physician-patient relationship. APRNs without full practice authority collaborate with physicians under written agreements (§54.5). No IDFPR statement on elective IV hydration, prior exams or mobile IV services was located.

The 'physician-patient relationship' condition still implies an individual relationship with each patient. Check IDFPR for IV-hydration guidance.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide classifies Illinois as strict, citing 225 ILCS 60/22, Dr. Allison, Dentist, Inc. v. Allison (1935) and Berlin v. Sarah Bush Lincoln Health Center (which recognized a licensed-hospital exception). MedPath Compliance (reviewed 2026-06-20) also rates Illinois strict and reports that HB 5000, a health-care transaction notice bill, passed both chambers on 2026-05-28.

Year of the Berlin decision is from general knowledge of the case; Permit Health cites it without a year.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

225 ILCS 60/54.2(e) authorizes IDFPR rules on physician delegation, including the use of light-emitting devices, and provides that an on-site physician examination before a non-ablative laser procedure is not required when (1) the laser hair removal facility follows a physician delegation protocol available to the Department, (2) the exam is done by an APRN, (3) the procedure is delegated by a physician and performed by an RN or LPN with documented training on each system, and (4) a physician is available by phone or electronically. Unlicensed persons may perform delegated tasks only in an office setting with a licensed professional on site (§54.2(b)).

The underlying IDFPR rule that otherwise requires an on-site physician exam was not fetched. The section was amended by P.A. 104-796 effective 2026-08-07; the specific change was not compared.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Illinois was not among them, but this research did not confirm its statutes. Illinois's CLIA state agency is Illinois Dept. of Public Health, Division of Health Care Facilities & Programs (DPH.CLIA@illinois.gov, 217-782-6747); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Illinois's rule. Illinois's lab regulator (CLIA state agency) is Illinois Dept. of Public Health, Division of Health Care Facilities & Programs (DPH.CLIA@illinois.gov, 217-782-6747). The question matters for take-home and consumer test kits, not for panels a clinician orders.

A commercial 2026 guide (Just Labs) groups Illinois with partially restrictive states; not confirmed against state law. The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Illinois is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Illinois is listed among the states banning the sale of cosmetics tested on animals. Under SB 561 as amended by HB 2516, selling, offering or distributing cosmetics with intentionally added PFAS will be prohibited from Jan 1, 2032.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed. Federal MoCRA and FDA cosmetic and OTC sunscreen rules apply in every state.